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6-Phosphofructo 2-kinase/fructose 2,6-bisphosphatase (PFK-2/FBPase-2) catalyses 
the formation and degradation of fructose 2,6-bisphosphate and is also a glucokinase-
binding protein.  The role of fructose 2,6-bisphosphate in regulating glucose 
metabolism and insulin secretion in pancreatic beta-cells is unresolved.  We down 
regulated the endogenous isoforms of PFK-2/FBPase-2 with siRNA and expressed 
kinase-active and kinase-deficient variants to distinguish between the role of PFK-
2/FBPase-2 protein as distinct from its product fructose 2,6-bisphosphate in regulating 
beta-cell function.  Human islets expressed the PFKFB2 and PFKFB3 isoforms and 
mouse islets expressed PFKFB2 at mRNA level (RT-PCR).  Rat islets expressed 
PFKFB2 lacking the C-terminal phosphorylation sites.  The glucose-responsive MIN6 
and INS1E cell lines expressed PFKFB2 and PFKFB3.   PFK-2 activity and the cell 
content of fructose 2,6-bisphosphate were increased by elevated glucose concentration 
and during pharmacological activation of AMP-activated protein kinase which also 
increased insulin secretion.  Partial down-regulation of endogenous PFKFB2 and 
PFKFB3 in INS1E  by siRNA decreased PFK-2/FBPase-2 protein, fructose 2,6-
bisphosphate content, glucokinase activity and glucose-induced insulin secretion.  
Selective down-regulation of glucose-induced fructose 2,6-bisphosphate in the 
absence of downregulation of PFK-2/FBPase-2 protein, using a kinase-deficient PFK-
2/FBPase-2 variant resulted in sustained glycolysis and elevated glucose-induced 
insulin secretion indicating an over-riding role of PFK-2/FBPase-2 protein, as distinct 
from its product fructose 2,6-bisphosphate, in potentiating glucose-induced insulin 
secretion.  Whereas down-regulation of PFK-2/FBPase-2 decreased glucokinase 
activity, overexpression of PFK-2/FBPase-2 only affected glucokinase distribution.  It 
is concluded that PFK-2/FBPase-2 protein rather than its product fructose 2,6-
bisphosphate is the over-riding determinant of glucose-induced insulin secretion 
through regulation of glucokinase activity or subcellular targeting. 
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INTRODUCTION 
 
6-Phosphofructo 2-kinase/fructose 2,6-bisphosphatase (PFK-2/FBPase-2) is a 
bifunctional enzyme that catalyses the synthesis and the degradation of fructose 2,6-
P2, a potent allosteric activator of the glycolytic enzyme, phosphofructokinase-1 
(PFK-1) [1,2] The N-terminal half acts as a kinase to catalyse the ATP-dependent 
phosphorylation of fructose 6-P to fructose 2,6-P2 whilst the C-terminal half acts as a 
bisphosphatase [2].  An unequivocal role for fructose 2,6-P2 as a regulator of 
glycolysis is established for a number of tissues including liver and heart [1,3,4], but 
whether fructose 2,6-P2 has a physiological role in control of glycolysis and insulin 
secretion in pancreatic islets remains unclear [5-7]. 
There are 4 isozymes of PFK-2/FBPase-2 designated liver, heart, brain and 
testis, encoded by genes PFKFB 1 to 4, respectively [2].   Differential splicing of 
these genes gives rise to isoforms that share conservation of the catalytic core but 
differ in the length of the N and C-terminal regions that contain phosphorylation sites 
that regulate the kinase or bisphosphatase activity.  The PFKFB1 gene encodes the 
liver and skeletal muscle isoforms, which differ in the length of the N-terminus.   The 
liver isoform is regulated by phosphorylation of ser-32 by cAMP-dependent protein 
kinase, which causes inhibition of the kinase and activation of the bisphosphatase, 
causing depletion of fructose 2,6-P2 and suppression of glycolysis [8]. 
Dephosphorylation of P-ser-32 is catalysed by a type-2A phosphatase that is activated 
by xylulose 5-P.  The increase in fructose 2,6-P2 caused by elevated glucose is 
explained by an increase in xylulose 5-P which activates the phosphatase and 
dephosphorylates PFK-2/FBPase-2 [9].  The muscle isoform lacks the first 32 
residues and is not regulated by cAMP [2].  The heart-type isoform encoded by 
PFKFB2 and the brain/inducible isoform encoded by PFKFB3 are activated (increase 
in kinase/ bisphosphatase activity) by phosphorylation of Ser-466 (heart) or Ser-461 
(brain) by AMP-activated protein kinase resulting in increased fructose 2,6-P2 [10-
12].  The heart isoform also has additional phosphorylation sites at the N-terminus 
(ser-94) and C-terminus (ser-475, ser-483) that can be phosphorylated by protein 
kinase C, calmodulin-dependent kinases and kinases activated by insulin and growth 
factor signalling [2].  Various splice variants have been reported for both PFKFB2 
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and PFKFB3 in human and rat tissue which differ in the C-terminal domain and 
therefore in their regulatory properties [13-16].   
Two independent studies on rat pancreatic islets have reported the expression 
of an isoform of the PFKFB2 gene that does not contain the Ser-466 phosphorylation 
site [17,18].  The more recent study by Baltrsuch and colleagues also reported the 
presence of a novel splice variant of PFKFB2, although as a minor form [18].   
Malaisse and colleagues reported that glucose caused a large increase in fructose 2,6-
P2 in rat islets similar to the increment in hepatocytes except that the effect was more 
rapid [5,6]. Since islets do not express the liver isoform of PFK-2/FBPase-2, the 
glucose effect has been suggested to be due to an increase in the concentration of 6-
phosphogluconate, which inhibits the bisphosphatase activity [17].  A later study on 
rat islets, reported much more modest effects of glucose on fructose 2,6-P2 [7].   
Work by Baltrusch and colleagues identified PFK-2/FBPase-2 as a 
glucokinase binding protein [18] and subsequent work in beta-cells focused on the 
possible role of PFK-2/FBPase-2 in regulating glucokinase activity [19,20].  
However, the question whether fructose 2,6-P2 has a role in pancreatic beta-cells in 
control of glucose metabolism and insulin secretion through either activation of PFK-
1 or other mechanisms as reported for other tissues [21] has not been addressed.    
In this study we investigated the role of endogenous PFK-2/FBPase-2 in 
control of insulin secretion by use of si-RNA to down-regulate the endogenous 
isoforms and we used kinase-active and kinase-deficient variants to distinguish 
between a role for fructose 2,6-P2 as distinct from a non-catalytic role for PFK-
2/FBPase-2 protein in regulating beta cell function.   
 
 
EXPERIMENTAL 
 
Isolation of pancreatic islets  Pancreatic islets were isolated from male C57/BL6 
mice (age 12-16 weeks) and male Wistar rats (body weight 180-220g).  The pancreas 
was injected with 1.5mg/ml liberase (Roche) in Ringer Phosphate Buffer (10mM 
Hepes (pH 7.4), 90mM NaCl, 5mM NaHCO3, 4.8mM KCl, 0.7mM KH2PO4, 0.6mM 
MgSO4 2.5mM CaCl2, 0.1% BSA, 5.5mM glucose) and shaken in the same medium 
for 6 min with further digestion with 0.75mg/ml liberase for 2-6min.  After washing 
in enzyme-free buffer and islets were picked and mRNA extracted from 50 (rat) or 
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100 (mouse) islets using micro-spin columns (Qiagen).  Human islets were isolated 
from pancreases retrieved from heart-beating deceased human donors following 
ethical approval and informed consent from donor relatives.  Cold ischemic time was 
< 9 h.  Islets were isolated at King's College Islet Isolation Facility, London [22] and 
transported to Newcastle University in Islet transport Medium (CMRL 1066-
Supplemented, (Cellgro, Herndon, VA) containing 5% human serum albumin).  Islet 
viability was > 90% and purity > 70%.  Islet RNA was extracted using GeneElute 
Mammalian Total RNA extraction kit (Sigma-Alrich) and RNasin(r) Plus RNase 
Inhibitor (Promega) to prevent RNA degradation. 
 
Cell lines and hepatocyte culture MIN6 (p20-27) and INS1E were cultured as 
described previously [23].  Hepatocytes were isolated from male Wistar rats and were 
suspended in MEM containing with 5% (v/v) newborn calf serum (Invitrogen) and seeded in 
multi-well plates [24].   
 
Treatment with adenoviral vectors  Adenoviral vectors for expression of kinase- 
deficient (KD) and kinase-active (KA) variants of PFK-2/FBPase-2 and glucokinase 
were described previously [21,25].  Adenoviral stocks were prepared by replication in 
293 cells and tested for their effects on enzyme activity (glucokinase) or fructose 2,6-
P2 (PFK-2/FBPase-2 variants).  They were then used at titres that altered glucokinase 
or fructose 2,6-P2 by up to 4 fold relative to endogenous levels.  Cells were treated 
with adenoviral vectors (2-2.5 fold increments) at either 2 h (hepatocytes) or 24 h 
(MIN6) after plating, for 2 h (hepatocytes) or 6 h (MIN6).  Cells were then cultured 
for 24 h to allow protein expression.  
 
Treatment with siRNA  INS1E cells were transfected either with scrambled siRNA 
(Allstar negative control, Qiagen) or with siRNA targeted against PFKFB2 and 
PFKFB3 isoforms (Rat PFKFB2 (SI01960014), Rat PFKFB3 (SI01960035), Qiagen) 
using lipofectamine 2000 (Invitrogen).  Cells were incubated for 72h to allow for 
silencing.     
 
Real time RT-PCR  Cellular RNA was extracted using TRIzol (Invitrogen) and 
treated with DNaseI (Roche, East Sussex, UK).  Single strand cDNA was synthesized 
from 1µg of total RNA with random hexamers and Superscript II (Invitrogen).  Real-
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time RT-PCR was performed in a total volume of 10µl containing 50ng of reverse 
transcribed total RNA and 5ng of forward and reverse primers (Table 1).  The 
reactions were carried out in capillaries in a Light Cycler (Roche) with initial 
denaturation at 95°C for 10min followed by 40 cycles consisting of 95°C for 15sec, 
60°C for 7sec and 72°C for 15sec.  The relative amount of PFKFB mRNA was 
corrected relative to the 18s mRNA.  The amplification of the correct PCR fragments 
was confirmed by DNA sequencing. 
 
Insulin secretion and glycolysis  MIN6 and INS1E were cultured in 24-well plates 
and washed with Krebs-Ringer Buffer [26].  They were then preincubated for 30min 
at 37C in glucose-free buffer, followed by a 1h incubation at the indicated glucose 
concentration with [3-3H]glucose  for the determination of glycolysis and insulin 
secretion.  Insulin was determined in the medium using a Rat Insulin Elisa Kit 
(Mercodia).  For hepatocytes, glycolysis was determined as described previously [24].   
 
Determination of metabolites and enzyme activity  For determination of fructose 
2,6-P2, MIN6 and INS1E were extracted into 0.05M NaOH and hepatocytes in 0.1 M 
NaOH and heated for 5 min at 80°C. Fructose 2,6-P2 was determined as in [27].  For 
determination of ATP cells were extracted in 3% perchloric acid and ATP was 
determined fluorimetrically [28].   Glucokinase activity in MIN6 was determined in 
13,000g supernatants of sonicated extracts as described in [29].  For elution in 
digitonin, MIN6 were incubated with 0.04 mg/ml digitonin in 150mM KCl, 3mM 
Hepes, 2 mM DTT for 4 minutes and glucokinase activity was determined on the 
digitonin extract [29].  PFK-2 activity was determined as in [23]. 
 
Western Blotting  Proteins were fractionated by SDS-PAGE and transferred to 
Nitrocellulose [26]. Membranes were then blotted for: glucokinase immunoreactivity 
(rabbit antibody against human glucokinase residues 318-405 (Santa Cruz)) and PFK-
2/FBPase-2 immunoreactivity with an antibody to the bisphosphatase domain raised 
in chicken [18] and AMPK-Thr-172(P) (New England Biolabs).   
 
Statistical Analysis  Results are expressed as means -/+ SEM based on 3-6 individual 
experiments except for Figures 4D and 8D, which represent replicates within a single 
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experiment.  Statistical analysis was by either ANOVA followed by the Bonferroni 
test or paired t-test using the Prism analysis programme. 
 
RESULTS 
 
mRNA expression of PFK-2/FBPase-2 isoforms in islets and beta-cell lines 
Previous studies on rat islets reported the expression of either the heart [17] or brain 
[18] isoforms of PFK-2/FBPase-2 lacking the C-terminal phosphorylation sites.  
However, the isoforms expressed in human and mouse islets or the MIN6 and INS1E 
glucose-responsive beta-cell lines have not been reported.  Using isoform-specific 
primers we determined the expression of PFKFB1-3 in the cell lines and in rat (Fig. 
1A-C), mouse (Fig. 1D-F) and human (Fig. 1H) islets.  RNA from rat and mouse 
liver, heart and brain was used as positive controls for the rat and mouse primers.  Rat 
islets expressed PFKFB2, with isoforms PFKFB1 and PFKFB3 being almost 
undetectable (Fig. 1A-C), whilst mouse islets also expressed predominantly PFKFB2, 
with low levels of PFKFB1 and PFKFB3 (Fig. 1D-F).  Human islets expressed 
PFKFB2 and PFKFB3, with isoform PFKFB1 being almost undetectable (Fig. 1H).  
Using primers to the C-terminal phosphorylation site ser-466 of PFKFB2 we 
confirmed that both mouse and human islets express this C-terminal region.  
However, rat islets did not express the region around the ser-466 phosphorylation site 
(Fig. 1G, H), consistent with previous findings [17,18].  INS1E (rat, Fig. 1A-C) and 
MIN6 (mouse, Fig. 1D-F) expressed mainly PFKFB2 and PFKFB3.   In MIN6 as in 
mouse islets, the PFKFB2 C-terminal ser-466 phosphorylation site was expressed at 
high levels (compared with heart).  INS1E expressed high levels of PFKFB2 mRNA 
compared to heart tissue (6-8 fold, Fig. 1B) but low levels of the C-terminal ser-466 
region.  Increasing passage number of INS1E (p110-p153) and MIN6 (p19-p35) had 
negligible effect on the PFKFB expression profile.   
 
Increase in fructose 2,6-P2 by pharmacological activation of AMPK 
Tissues that express the heart or brain isoforms show elevation of fructose 2,6-P2 
during pharmacological activation of AMPK with oligomycin (which inhibits ATP 
synthetase) or AICAR (which is phosphorylated to ZMP, an AMP analogue) as a 
result of phosphorylation of ser-466 (heart isoform) or ser-461 (brain isoform) which 
increases the kinase activity of PFK-2/FBPase-2 [10,11].  We therefore tested whether 
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these pharmacological activators of AMPK affect fructose 2,6-P2 levels in MIN6 and 
INS1E.   Preliminary studies testing the effects of AICAR (100 – 500 µM) showed a 
concentration-dependent increase in fructose 2,6-P2 (control 100%; 100 µM, 114 ± 
14;  200 µM 133 ± 9; 500 µM 200 ± 19).   At the highest concentration tested, 
AICAR (500 µM) also increased cellular ATP (untreated, 6.5 ± 0.3; AICAR, 9.0 ± 0.6 
nmol/mg protein, P < 0.003).  However, 500 µM AICAR decreased glycolysis (80 ± 
11% relative to control).  Subsequent experiments on glycolysis and insulin secretion 
were therefore performed at AICAR concentrations up to 200 µM. 
Incubation of MIN6 with 0.5 µM oligomycin for 2-10 min or with 200 µM AICAR 
for 1 h increased the phosphorylation of AMPK-Thr-172 consistent with activation of 
the enzyme (Fig. 2A and 2B).  This was associated with a biphasic increase in 
fructose 2,6-P2 after addition of oligomycin (Fig. 2A) and a sustained increase during 
incubation with AICAR (Fig 2B).  AICAR (200 µM) increased insulin secretion at 25 
mM glucose but had no effect on glycolysis  (Fig. 2C,D).  The increase in fructose 
2,6-P2 by AICAR in MIN6 was associated with an increase in kinase activity of PFK-
2/FBPase-2  (Fig. 2E).  This is consistent with expression of the C-terminal 
phosphorylation sites of the heart and / or brain isoforms and contrasts with the 
suppression of kinase activity by AICAR in hepatocytes (Fig. 2F), which express a 
different isoform of  PFK-2/FBPase-2 (PFKFB1).  The fructose 2,6-P2 content was 
also increased in mouse islets by AICAR (Fig. 3A) and in INS1E cells with AICAR 
(1.4 fold) and with oligomycin (1.2 fold at 2 min,  P < 0.05).  .   
 
Glucose-dependent regulation of fructose 2,6-P2 in MIN6 and INS1E cells  
The fructose 2,6-P2 content was glucose responsive in islets, MIN6 and INS1E cells.  
In rat and mouse islets it was increased by 57-69 % at 25 mM compared with 5 mM 
glucose (Fig. 3A).  Fructose 2,6-P2 was 2-fold higher in MIN6 than in INS1E at 5 mM 
glucose and it was increased by 50% and 3-fold, respectively at 35mM glucose (Fig. 
3B).  In MIN6 cells the kinase activity of PFK-2/FBPase-2 was slightly but 
significantly (P < 0.05) higher at 25 mM compared with 5 mM glucose (5mM, 4.0 ± 
0.3; 25 mM 4.9 ± 0.3, n=8) suggesting that the effect of glucose is at least in part due 
to covalent modification of PFK2/FBPase-2. 
Because 6-phosphogluconate is an inhibitor of the bisphosphatase activity of PFK-
2/FBPase-2 and is elevated by high glucose concentration [17], we next tested the 
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effects of epiandrosterone, an inhibitor of glucose 6-phosphate dehydrogenase.  
Epiandrosterone caused a concentration-dependent suppression of fructose 2,6-P2, in 
MIN6 and INS1E (Fig. 4A-B), consistent with a possible role for 6-phosphogluconate 
or downstream metabolites of the pentose phosphate pathway in increasing fructose 
2,6-P2, and it suppressed glucose-induced insulin secretion (Fig. 4C).   At 25 mM 
glucose, epiandrosterone suppressed but did not totally abolish the increase in fructose 
2,6-P2 caused by AICAR (Fig. 4D).   Kinase activity of PFK-2/FBPase-2 measured in 
parallel conditions as in Fig. 4D (control, 2.1 ± 0.1; epiandrosterone, 1.9 ± 0.1; 
AICAR 3.0 ± 0.2; AICAR + epiandrosterone 2.1 ± 0.2, n=4) was decreased by the 
inhibitor in the presence (P < 0.05) but not in the absence of AICAR.  The latter is 
consistent with a role for 6-phosphogluconate in suppressing fructose 2,6-P2 by 
competitive inhibition of the bisphosphatase activity of PFK-2/FBPase-2 [17]. 
 
The role of endogenous PFK-2/FBPase-2 in pancreatic beta cells 
To date, studies investigating the role of PFK-2/FBPase-2 in regulating glucokinase 
activity in beta-cells have relied on PFK-2/FBPase-2 overexpression in cells 
expressing either endogenous or overexpressed glucokinase [19,20].  To determine 
the role of endogenous PFK-2/FBPase-2 in pancreatic beta cells, we used siRNA 
against PFKFB2 and PFKFB3 to downregulate endogenous enzyme.  Silencing was 
confirmed by a 50% decrease in the mRNA levels of PFKFB2 and PFKFB3 (Fig. 5A) 
and by a 40-50% decrease in immunoreactivity to PFK-2/FBPase-2 and in fructose 
2,6-P2 content (Fig. 5B-C).  Combined down-regulation of PFKFB2 and PFKFB3 
suppressed insulin secretion at 25 mM glucose and also glucokinase activity.   Rates 
of glycolysis and glucokinase immunoreactivity were not significantly changed (Fig. 
5D-F). 
 
The role of fructose 2,6-P2 in pancreatic beta cells 
To distinguish between a role for PFK-2/FBPase-2 protein as distinct from fructose 
2,6-P2 in regulating glucokinase activity and insulin secretion we used adenoviral 
vectors expressing either kinase-active (KA) or kinase-deficient (KD) variants of 
PFK-2/FBPase-2 to up-regulate and down-regulate fructose 2,6-P2, respectively.  We 
validated these variants in hepatocytes, where the role of fructose 2,6-P2 in control 
glycolysis is well established.  Titrated expression of KA- PFK-2/FBPase-2 resulted 
in a 2-fold increase in fructose 2,6-P2 and in a small increase in glycolysis (Fig. 6A-
 11 
B), whereas expression of KD- PFK-2/FBPase-2 decreased fructose 2,6-P2 and 
glycolysis (Fig. 6C-D) similarly to glucagon (Fig. 6E).  This confirms that 
suppression of glycolysis by glucagon is due to suppression of fructose 2,6-P2. 
Titrated expression of KA- PFK-2/FBPase-2 in MIN6 cells resulted in an increase in 
fructose 2,6-P2 during incubation with 5 mM glucose and in an increase in glycolysis 
and insulin secretion (Fig. 7A-C).  Cellular ATP was unchanged in cells expressing 
KA-PFK-2/FBPase-2 (n=2, results not shown).  Titration with the KD-PFK-
2/FBPase-2 lowered fructose 2,6-P2 by 50% at 15mM glucose (Fig. 7D).  However, 
unlike in hepatocytes, glycolysis showed a small apparent increase (Fig. 7E).  Insulin 
secretion was similarly increased by the two variants despite the converse changes in 
fructose 2,6-P2  (Fig. 7F). 
 
Activation of glucokinase by PFK-2/FBPase-2 in pancreatic beta cells 
We determined whether an increase in glucokinase activity could explain the increase 
in glucose-induced insulin secretion by the KA and KD variants of PFK-2/FBPase-2.  
Glucokinase activity in the cytosol fraction (13,000g supernatant of sonicated 
extracts) was not increased in cells overexpressing KA-PFK-2/FBPase-2 (Fig. 8A) or 
KD- PFK-2/FBPase-2 (results not shown).   However, using a digitonin 
permeabilisation assay which elutes the free or unbound enzyme, there was a higher 
glucokinase activity eluted from cells overexpressing KA-PFK-2/FBPase-2 (Fig. 8B).   
Since expression of PFK-2/FBPase-2 increases glucokinase activity in cytosol 
extracts of MIN6 expressing GK-GFP chimaeras but not in untransfected MIN6 [26], 
we determined the effects of separate and combined overexpression of glucokinase 
and KA- PFK-2/FBPase-2 in MIN6 cells (Fig. 8C).   Whereas overexpression of 
either enzyme alone had little effect on glucose-induced insulin secretion, combined 
overexpression of both proteins stimulated insulin secretion, similar to the effect of a 
glucokinase activator (Fig. 8D). 
 
DISCUSSION 
 
Three key findings emerged from this study.  First, that the cell content of 
fructose 2,6-P2 in beta cells is regulated by glucose and by activation of AMPK.  The 
latter was associated with activation of the kinase activity of PFK-2/FBPase-2 and is 
consistent with the expression of PFKFB2 and PFKFB3 isoforms.   Second, that in 
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pancreatic beta-cells endogenous PFK-2/FBPase-2 has a critical role in regulation of 
cell function as shown by the decrease in total glucokinase activity and glucose-
induced insulin secretion during partial down regulation of endogenous PFK-
2/FBPase-2 isoforms by siRNA.   Third, by using kinase-deficient and kinase-active 
variants of PFK-2/FBPase-2 we demonstrate an over-riding role of PFK-2/FBPase-2 
protein as distinct from its catalytic activity in regulating glucokinase activity.  This 
does not rule out an additional role for fructose 2,6-P2 in the control of metabolic 
oscillations and / or pulsatile insulin secretion. 
Several allosteric effectors are involved in the regulation of PFK-1 and 
thereby glycolysis.   They include both inhibitors (ATP, citrate, phosphoenolpyruvate) 
and activators (ADP, AMP, fructose 1,6-P2, glucose 1,6-P2, 6-phosphogluconate, 
fructose 2,6-P2).   Of these fructose 2,6-P2 is the most potent effector with an 
activation constant in the nanomolar or micromolar range depending on the 
concentrations of other effectors [1].  The relative sensitivity of PFK1 to these 
effectors is isoform dependent, with the M (muscle) isoform, having a relatively 
higher affinity for fructose 1,6-P2 and lower affinity for fructose 2,6-P2 compared with 
the L (liver) and C (platelet) isoforms [31,32].  Rat pancreatic islets express 
predominantly the C-isoform with lower levels of M and L isoforms [33], and both 
deficiency in M and overexpression of the L-isoform are associated with impaired 
insulin secretion suggesting a critical role for the different isoforms in islets [34,35]. 
The regulation of the cell content of fructose 2,6-P2 is dependent on the 
PFKFB isoforms expressed.  In liver which expresses PFKFB1, the fructose 2,6-P2 
content is regulated by cAMP [8] and by glucose through a xylulose 5-P dependent 
type 2A phosphatase [9], whereas in heart and monocytes which express PFKBP2 and 
PFKBP3, it is regulated by AMPK activity [10,11].  In the latter tissues the 
stimulation of glycolysis by anoxia could be attributed to activation of PFK1 by either 
AMP or by the elevated fructose 2,6-P2.  The specific contribution of the latter 
mechanism has not been determined [11].    We show in this study that in mouse islets 
and pancreatic beta-cell lines the fructose 2,6-P2 content is increased by glucose and 
by pharmacological activation of AMPK.  The latter was associated with activation of 
the kinase activity of PFK-2/FBPase-2 and is consistent with expression in mouse 
islets and beta-cell lines of PFKFB2 and PFKFB3.  The lack of concomitant 
stimulation of glycolysis during incubation with AICAR despite activation of AMPK, 
could be due to either inhibition of PFK1 by ZMP as shown for the FTO2B hepatoma 
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[36], or to inhibition of glucose phosphorylation [37].   In hepatocytes AICAR 
inhibits glucose phosphorylation by an AMPK-independent mechanism involving 
inhibition of glucokinase translocation from the nucleus to the cytoplasm [38] and / or 
inhibition og glucokinase activity by ZMP [37].  In pancreatic beta cells glucokinase 
does not shuttle between the nucleus and cytoplasm as in hepatocytes.   However, 
inhibition of glucokinase by ZMP [37] cannot be firmly excluded.    
In pancreatic beta cells both stimulation and inhibition of insulin secretion 
during activation of AMPK with AICAR has been reported [39-42].  In this study 
AICAR stimulated insulin secretion and increased cellular ATP, despite the lack of 
stimulation of glycolysis.   It is possible that the variable effects of AICAR on insulin 
secretion in different studies may reflect the net changes in ATP/ADP.  Differences in 
cell culture conditions such as the folate content of the medium, which affects the 
metabolism of ZMP may account for variability in cellular ATP with AICAR 
treatment [36].    
We found that rat islets express PFKFB2 lacking the C-terminal AMP-kinase 
motif, consistent with previous findings of a truncated heart isoform [17,18].  The 
apparent species difference between rat islets and murine and human islets is 
surprising.  We cannot rule out age-dependent differences in isoform expression as 
shown for PFK-1 [43].  This might in part explain the wide variation in the rat islet 
content of fructose 2,6-P2 reported previously [5-7].  Although the truncated 
PFK2FB2 lacks the terminal AMPK motif (ser-466), it has two putative AMPK 
motifs (ser-58 and ser-86) with a hydrophobic residue at P-5 and a basic residue at P-
3/-4, consistent with these sites being potential substrates for both AMPK and cAMP 
dependent protein kinase [44], which causes activation of the heart isoform [45].   
The present finding that the fructose 2,6-P2 content of beta-cells is elevated 
during activation of AMPK, raises the question of the possible role of this mechanism 
in beta-cells.   A tentative hypothesis is that the increase in fructose 2,6-P2 may have a 
role in pulsatile insulin secretion which is attributed to oscillations in glycolysis and 
in the ATP/ADP ratio [46-49].   Pulsatile insulin secretion occurs both in vivo and in 
perifused islets and clonal beta-cells in vitro and is attributed to oscillations in the 
ATP/ADP ratio and in metabolites of glycolysis.  Metabolic oscillations are not 
unique to beta-cells but also occur in other cell types and in muscle and heart extracts 
[50].  The oscillations in cell extracts involve converse fluctuations in hexose 
monophosphates (glucose 6-P and fructose 6-P) and fructose 1,6-P2, indicating 
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repetitive activation and inactivation of PFK1.   The inactivation phase is preceded by 
the rise in ATP/ADP, whereas the activation of PFK1 is preceded by the decline in 
ATP/ADP ratio.   The latter has been conventionally explained in skeletal muscle by 
the rise in fructose 1,6-P2 which is a high-affinity activator of the muscle PFK1 
isoform [50].  It can be hypothesized that in tissues expressing the PFKFB2 and 
PFKFB3 isoforms such as islets (which also express the C and L PFK1 isoforms), the 
metabolic oscillations may involve activation of AMPK during the decline in 
ATP/ADP resulting in an increase in fructose 2,6-P2 and activation of the C/L 
isoforms of PFK1.  Loss of pulsatile insulin secretion in both human type 2 diabetes 
and animal models is well documented [46], and may be due to age-dependent 
changes in the expression of either PFK-1 [34,35,43] or PFK-2/FBPase-2 isoforms.  
This study provides evidence for control of fructose 2,6-P2 by glucose (25mM 
vs 5 mM) in pancreatic islets and in MIN6 and INS1E cell lines.  Glucose may impact 
the fructose 2,6-P2 content by covalent modification of PFK-2/FBPase-2 or through 
changes in concentrations of metabolites that act as activators or inhibitors of either 
the kinase or bisphosphatase activity.  Elevated glucose may cause a decrease in 
AMPK activity [40,41], which would be expected to decrease the kinase activity of 
PFK-2/FBPase-2 and thereby the cell content of fructose 2,6-P2.  However, in this 
study elevated glucose caused an increase in kinase activity of PFK-2/FBPase-2.  This 
suggests that glucose causes covalent modification of PFK-2/FBPase-2, by a 
mechanism that over-rides any effect resulting from glucose-induced suppression of 
AMPK [40,41].   The increase in fructose 2,6-P2 caused by glucose can be explained 
by both covalent modification of PFK-2/FBPase-2, as shown by the increase in kinase 
activity and by an increased concentration of 6-phosphogluconate (a competitive 
inhibitor of the bisphosphatase activity) as a result of increased flux through the 
pentose phosphate pathway [17].  The marked suppression of fructose 2,6-P2 with 
epiandrosterone, in the absence of a corresponding decrease in kinase activity of PFK-
2/FBPase-2 is consistent with a role for 6-phosphogluconate as an inhibitor of the 
bisphosphatase.    
The higher fructose 2,6-P2 content in the cell lines compared with islets (10-25 
vs 3 pmol/mg) may be related to the elevated flux through the pentose phosphate 
pathway in proliferating cells.  Since 6-phosphogluconate is an activator of PFK1 
[31,32] as well as an inhibitor of the bisphosphatase [17], the apparent refractoriness 
of glycolysis to fluctuations in fructose 2,6-P2 with the kinase-deficient variant in 
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MIN6 could be due to the elevated concentration of 6-phosphogluconate which may 
substitute for fructose 2,6-P2 in the regulation of PFK1 or to altered expression of 
PFK1 isoforms [33]. 
By using siRNA to down-regulate endogenous PFKFB2 and PFKFB3 this 
study demonstrates for the first time the critical role for PFK-2/FBPase-2 in beta-cell 
function.  Down-regulation of PFK-2/FBPase-2 protein by 50% resulted in a decrease 
in fructose 2,6-P2, in total glucokinase activity and glucose-induced insulin secretion.  
The lack of suppression of glucokinase activity or insulin secretion during down-
regulation of fructose 2,6-P2 with the kinase-deficient variant rules out a role for 
fructose 2,6-P2 in explaining the effects of down-regulation of PFK-2/FBPase-2.  Two 
mechanisms can be considered for the role of PFK-2/FBPase-2 in insulin secretion: 
either it determines subcellular targeting of glucokinase or it enhances or stabilises 
glucokinase catalytic activity.  The increase in glucokinase activity in the digitonin 
elutable fraction (though not in the cytosol fraction) suggests that overexpressed PFK-
2/FBPase-2 may affect the sub-cellular distribution of glucokinase.  In pancreatic 
beta-cells glucokinase associates with insulin granules and microtubules [ref].  The 
co-localisation of glucokinase and PFK-2/FBPase-2 with insulin granules as shown by 
both subcellular fractionation and fluorescence imaging [20,23], may play a role in 
determining the subcellular distribution of glucokinase.  The lack of increase in total 
glucokinase activity when kinase active PFK-2/FBPase-2 was overexpressed can be 
explained by a saturating role for the endogenous PFK-2/FBPase-2 protein in 
stabilising glucokinase.  Previous work showed that overexpression of PFK-
2/FBPase-2 increases glucokinase activity in MIN6 cells expressing GFP-GK 
chimaeras but not in non-transfected cells expressing only endogenous glucokinase 
[26].  This was explained by a role for endogenous PFK-2/FBPase-2 in stabilising 
endogenous glucokinase as in hepatocytes [24].  This study demonstrates that 
overexpression of either glucokinase or PFK-2/FBPase-2 alone has negligible effect 
on insulin secretion.  However, combined overexpression of both proteins stimulates 
insulin secretion (similar to a glucokinase activator) and also enhances glucokinase 
activity relative to overexpression of glucokinase alone.  This supports a model for 
co-ordinate control of insulin secretion by glucokinase and PFK-2/FBPase-2, 
consistent with the findings from the siRNA experiments, where suppression of PFK-
2/FBPase-2 led to a decrease in total glucokinase activity and in glucose-induced 
insulin secretion.   
 16 
 
Acknowledgements:   This work was supported by project and equipment grants from 
Diabetes UK (RDO1/0002364, RD05/0003049) and MRC (G100348, G0501543) to 
LA,CA.   We thank Dr GC Huang and Prof S Amiel for human islets provided as part 
of a collaborative research project (JAMS, AA, GH, DM) funded by the Diabetes 
Foundation including salary support for AA.  We thank Drs Claes Wollheim and Jun-
Ichi Miyazaki for the kind gift of the cell lines. 
 
References 
1. Hue, L,. and Rider, MH. (1987) Role of fructose 2,6-bisphosphate in the 
control of glycolysis in mammalian tissues. Biochem. J.  245, 313 –324 
2. Rider, M.H., Bertrand, L., Vertommen, D., Michels, P.A., Rousseau, G.G. and 
Hue, L.  (2004)  6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: head-
to-head with a bifunctional enzyme that controls glycolysis.  Biochem. J. 381, 
561-579 
3. Depre, C., Rider, M.H. and Hue, L.  (1998)  Mechanisms of control of heart 
glycolysis.  Eur. J. Biochem.  257, 277-290 
4. Hue, L., Beauloye, C., Marsin, A.-S., Bertrand, L., Horman, S. and Rider, 
M.H.  (2002)  Insulin and ischemia stimulate glycolysis by acting on the same 
targets through different and opposing signaling pathways.  J. Mol. Cell. 
Cardiol.  34, 1090-1097 
5. Malaisse, W.J., Malaisse-Lagae, F. and Sener, A.  (1982)  Glucose-induced 
accumulation of fructose-2,6-bisphosphate in pancreatic islets.  Diabetes.  31, 
90-93 
6. Sener, A., Van Schaftingen, E., Van de Winkel, M., Pipeleers, D.G., Malaisse-
Lagae, F., Malaisse, W.J. and Hers, HG.  (1984)  Effects of glucose and 
glucagon on the fructose 2,6-bisphosphate content of pancreatic islets and 
purified pancreatic B-cells. A comparison with isolated hepatocytes.  
Biochem. J.  221, 759-764 
7. Burch, P.T., Berner, D.K., Najafi, H., Meglasson, M.D. and Matschinsky, 
F.M.  (1985)  Regulatory role of fructose-2,6-bisphosphate in pancreatic islet 
glucose metabolism remains unsettled.  Diabetes.  34, 1014-1018. 
8. Kurland, I.J., El-Maghrabi, M.R., Correia, J.J. and Pilkis, S.J. (1992)  Rat liver 
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. Properties of phospho- 
and dephospho- forms and of two mutants in which Ser32 has been changed 
by site-directed mutagenesis. J. Biol. Chem.  267, 4416 –4423 
9. Nishimura, M., Fedorov, S. and Uyeda, K.  (1994)  Glucose-stimulated 
synthesis of fructose 2,6-bisphosphate in rat liver. Dephosphorylation of 
fructose 6-phosphate, 2-kinase:fructose 2,6-bisphosphatase and activation by a 
sugar phosphate.  J. Biol. Chem.  269, 26100-26106 
10. Marsin, A.-S., Bertrand, L., Rider, M.H., Deprez, J., Beauloye, C., Vincent, 
M.F., Van den Berghe, G., Carling, D. and Hue, L.  (2000).  Phosphorylation 
and activation of heart PFK-2 by AMPK has a role in the stimulation of 
glycolysis during ischaemia.  Curr. Biol. 10, 1247-1255 
 17 
11. Marsin, A.-S., Bouzin, C., Bertrand, L. and Hue, L.  (2002)  The stimulation 
of glycolysis by hypoxia in activated monocytes is mediated by AMP-
activated protein kinase and inducible 6-phosphofructo-2-kinase.  J. Biol. 
Chem.  277,30778-30783 
12. Almeida, A., Moncada, S. and Bolanos J.P.  (2004)  Nitric oxide switches on 
glycolysis through the AMP protein kinase and 6-phosphofructo-2-kinase 
pathway.  Nature Cell Biol.  6, 45-51 
13. Chikri, M. and Rousseau, G.G.  (1995)  Rat gene coding for heart 6-
phosphofructo-2-kinase/fructose-2,6-bisphosphatase: characterization of an 
unusual promoter region and identification of four mRNAs.  Biochemistry.  
34, 8876-8884 
14. Watanabe, F. and Furuya, E.  (2001)  Alternative splicing of novel exons of rat 
heart-type fructose-6-phosphate 2-kinase/fructose-2,6-bisphosphatase gene.  
Biochem. Biophys. Res. Comm.  282, 803-810 
15. Watanabe, F. and Furuya, E.  (1999)  Tissue-specific alternative splicing of rat 
brain fructose 6-phosphate 2-kinase/fructose 2,6-bisphosphatase.  FEBS Letts.  
458, 304-308 
16. Kessler, R. and Eschrich, K.  (2001)  Splice isoforms of ubiquitous 6-
phosphofructo-2-kinase/fructose-2,6-bisphosphatase in human brain.  Mol. 
Brain Res.  87, 190-195 
17. Sakurai, T., Johnson, J.H., Uyeda, K. (1996)  Islet fructose 6-phosphate, 2-
kinase:fructose 2,6-bisphosphatase: isozymic form, expression, and 
characterization.  Biochem. Biophys. Res. Comm.  218, 159-163 
18. Baltrusch, S., Lenzen, S., Okar, D.A., Lange, A.J. and Tiedge, M.  (2001)  
Characterization of glucokinase-binding protein epitopes by a phage-displayed 
peptide library. Identification of 6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatase as a novel interaction partner.  J. Biol. Chem.  276, 43915-
43923 
19. Massa, L., Baltrusch, S., Okar, D.A., Lange, A.J., Lenzen, S. and Tiedge, M.  
(2004)  Interaction of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 
(PFK-2/FBPase-2) with glucokinase activates glucose phosphorylation and 
glucose metabolism in insulin-producing cells.  Diabetes.  53, 1020-1029 
20. Baltrusch, S., Langer, S., Massa, L., Tiedge, M. and Lenzen, S.  (2006)  
Improved metabolic stimulus for glucose-induced insulin secretion through 
GK and PFK-2/FBPase-2 coexpression in insulin-producing RINm5F cells.  
Endocrinology.  147, 5786-5776 
21. Wu, C., Okar, D.A., Stoeckman, A.K., Peng, L., Herrera, A.H., Herrera, J.E., 
Towle, H.C. and Lange, A.J.  (2004)  A potential role for fructose-2,6-
bisphosphate in the stimulation of hepatic glucokinase gene expression.  
Endocrinology.  145, 650-658 
22. Huang, G.C., Zhao, M., Jones, P., Persaud, S., Ramracheya, R., Lobner, K., 
Christie, M.R., Banga, J.P., Peakman, M., Sirinivsan, P., Rela, M. and Heaton, 
N., Amiel, S.  (2004)  The development of new density gradient media for 
purifying human islets and islet-quality assessments.  Transplantation. 77, 
143-145 
23. Arden, C., Harbottle, A., Baltrusch, S., Tiedge, M. and Agius, L. (2004)  
Glucokinase is an integral component of the insulin granules in glucose-
responsive insulin secretory cells and does not translocate during glucose 
stimulation. Diabetes.  53, 2346-2352 
 18 
24. Payne, V.A., Arden, C., Wu, C., Lange, A.J. and Agius, L.  (2005)  Dual role 
of phosphofructokinase-2/fructose bisphosphatase-2 in regulating the 
compartmentation and expression of glucokinase in hepatocytes. Diabetes.   
54, 1949-1957. 
25. Becker, T.C., Noel, R.J., Johnson, J.H., Lynch, R.M., Hirose, H., Tokuyama, 
Y., Bell, G.I. and Newgard, C.B.  (1996) Differential effects of overexpressed 
glucokinase and hexokinase I in isolated islets. Evidence for functional 
segregation of the high and low Km enzymes. J. Biol. Chem. 271, 390-394 
26. Arden, C., Trainer, A., de la Iglesia, N., Scougall, K.T., Gloyn, A.L., Lange, 
A.J., Shaw, J.A., Matschinsky, F.M. and Agius, L.  (2007)  Cell biology 
assessment of glucokinase mutations V62M and G72R in pancreatic beta-
cells: evidence for cellular instability of catalytic activity. Diabetes.  56, 1773-
1782 
27. Van Schaftingen, E.  (1984).  Methods of Enzymatic Analysis. 3rd ed. 
Bergmeyer HU, Ed. Weinheim, Germany, Verlag Chemi. Vol vi  p.335 –341 
28. Trautschold, I., Lamprecht, W. and Schheitzer, G.  (1984) Methods of 
Enzymatic Analysis. 2nd Ed.   Germany, Verlag Chemi.  Vol vii.  p.346-357 
29. Stubbs, M., Aiston, S. and Agius, L. (2000) Subcellular localization, mobility, 
and kinetic activity of glucokinase in glucose-responsive insulin-secreting 
cells. Diabetes. 49, 2048-2055 
30. Bartrons, R., Hue, L., Van Schaftingen, E. and Hers, H.G. (1983) Hormonal 
control of fructose 2,6-bisphosphate concentration in isolated rat hepatocytes 
Biochem. J. 214, 829-837 
31. Sanchez-Martinez, C., Estevez, A.M. and Aragon, J.J.  (2000)  
Phosphofructokinase C isozyme from ascites tumor cells: cloning, expression, 
and Properties, Biochem. Biophys. Res. Commun. 271, 635-640 
32. Sommercorn, J., Steward, T. and Freedland, R.A.  (1984)  Activation of 
phosphofructokinase from rat tissues by 6-phosphogluconate and fructose 2,6-
bisphosphate. Arch. Biochem. Biophys. 232, 579-584 
33. Yaney, G.C., Schultz, V., Cunningham, B.A., Dunaway, G.A., Corkey, B.E. 
and Tornheim, K.  (1995)   Phosphofructokinase isozymes in pancreatic islets 
and clonal beta-cells (INS-1). Diabetes.  44, 1285-1289 
34. Ristow, M., Vorgerd, M., Mohlig, M., Schatz, H. and Pfeiffer, A.  (1997)  
Deficiency of phosphofructo-1-kinase/muscle subtype in humans impairs 
insulin secretion and causes insulin resistance. J. Clin. Invest. 100, 2833-2841 
35. Knobler, H., Weiss, Y., Peled, M. and Groner, Y.  (1997)  Impaired glucose-
induced insulin response in transgenic mice overexpressing the L-
phosphofructokinase gene. Diabetes. 46, 1414-1418 
36. Javaux, F., Vincent, M.F., Wagner, D.R. and van den Berghe, G.  (1995)  Cell-
type specificity of inhibition of glycolysis by 5-amino-4-
imidazolecarboxamide riboside. Lack of effect in rabbit cardiomyocytes and 
human erythrocytes, and inhibition in FTO-2B rat hepatoma cells. Biochem. J. 
305, 913-919 
37. Vincent, M.F., Bontemps, F. and Van den Berghe, G. (1992) Inhibition of 
glycolysis by 5-amino-4-imidazolecarboxamide riboside in isolated rat 
hepatocytes.  Biochem. J. 281, 267-272 
38. Guigas, B., Bertrand, L., Taleux, N., Foretz, M., Wiernsperger, N., 
Vertommen, D.,Andreelli, F., Viollet, B. and Hue, L.  (2006)   5-
Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside and metformin 
 19 
inhibit hepatic glucose phosphorylation by an AMP-activated protein kinase-
independent effect on glucokinase translocation. Diabetes 55, 865-74 
39. Wang, C.Z., Wang, Y., Di, A., Magnuson, M.A., Ye, H., Roe, M.W., Nelson, 
D.J., Bell, G.I. and Philipson, L.H.  (2005)  5-amino-imidazole carboxamide 
riboside acutely potentiates glucose-stimulated insulin secretion from mouse 
pancreatic islets by KATP channel-dependent and independent pathways. 
Biochem. Biophys. Res. Commun. 330, 1073-1079 
40. Salt, I.P., Johnson, G., Ashcroft, S.J. and Hardie, D.G.  (1998) AMP-activated 
protein kinase is activated by low glucose in cell lines derived from pancreatic 
beta cells, and may regulate insulin release. Biochem. J. 335, 533-539 
41. da Silva Xavier. G., Leclerc, I., Varadi, A., Tsuboi, T., Moule, SK. and Rutter, 
G.A.  (2003)  Role for AMP-activated protein kinase in glucose-stimulated 
insulin secretion and preproinsulin gene expression. Biochem. J. 371, 761-774 
42. Gleason, C.E., Lu, D., Witters, L.A., Newgard, C.B. and Birnbaum, M.J.  
(2007)  The role of AMPK and mTOR in nutrient sensing in pancreatic beta-
cells. J. Biol. Chem. 282, 10341-10351 
43. Dunaway, G.A., Kasten, T.P., Crabtree, S. and Mhaskar, Y.  (1990)  Age-
related changes in subunit composition and regulation of hepatic 6-
phosphofructo-1-kinase. Biochem. J.  266, 823-827 
44. Michell, B.J., Stapleton, D., Mitchelhill, K.I., House, C.M., Katsis, F., Witters, 
L.A. and Kemp, B.E.  (1996)  Isoform-specific purification and substrate 
specificity of the 5'-AMP-activated protein kinase. J. Biol. Chem. 271, 28445-
28450 
45. Depre, C., Ponchaut, S., Deprez, J., Maisin, L. and Hue, L.  (1998)  Cyclic 
AMP suppresses the inhibition of glycolysis by alternative oxidizable 
substrates in the heart. J. Clin. Invest.  101, 390-397 
46. Tornheim, K.  (1997)  Are metabolic oscillations responsible for normal 
oscillatory insulin secretion?  Diabetes. 46, 1375-1380 
47. Deeney, J.T., Kohler, M., Kubik, K., Brown, G., Schultz, V., Tornheim, K., 
Corkey, B.E. and Berggren, P.O.  (2001) Glucose-induced metabolic 
oscillations parallel those of Ca(2+) and insulin release in clonal insulin-
secreting cells. A multiwell approach to oscillatory cell behavior. J. Biol. 
Chem. 276, 36946-36950 
48. Nilsson, T., Schultz, V., Berggren, P.O., Corkey, B.E. and Tornheim, K.  
(1996)  Temporal patterns of changes in ATP/ADP ratio, glucose 6-phosphate 
and cytoplasmic free Ca2+ in glucose-stimulated pancreatic beta-cells. 
Biochem. J.  314, 91-94 
49. Juntti-Berggren, L., Webb, D.L., Arkhammar, P.O., Schultz, V., Schweda, 
E.K., Tornheim, K. and Berggren, P.O.  (2003)  Dihydroxyacetone-induced 
oscillations in cytoplasmic free Ca2+ and the ATP/ADP ratio in pancreatic 
beta-cells at substimulatory glucose. J. Biol. Chem.  278, 40710-40716 
50. Tornheim, K.  (1988)  Fructose 2,6-bisphosphate and glycolytic oscillations in 
skeletal muscle extracts. J. Biol. Chem.  263, 2619-2624 
 
 20 
 
 
Species Gene Primer Sequence 
Mouse PFKFB1 FWD: TCC ATG TCA CAC CTC GAT CT 
REV: GGA GCT GAT GCT TTG AGA CC 
NM_00824 
(808-943bp) 
 PFKFB2 FWD: ATG GAG CTA GAG CGT CAA GG 
REV: GGG GCA CCT CAA GTA TGG TA 
NM_008825 
(1252-1349bp) 
 PFKFB2 
(Ser466) 
FWD: TCT TGG ATA AAG GCG CAG AT 
REV: GAT TAG TGG CAA GGG CAA GA 
NM_008825 
(1325-1698bp) 
 PFKFB3 FWD: AGA ACT TCC ACT CTC CCA CCC  
REV: AGG GTA GTG CCC ATT GTT GAA  
NM_133232 
(1600-1999bp) 
Rat PFKFB1 FWD: GTT TAC CAG CTC GAG GCA AG 
REV: TGT TGT CTG GGC GAA AGA AT 
NM_12621 
(348-478bp) 
 PFKFB2 FWD: CCG AGG AAC TGG ATC TAC CA 
REV: ATG TTC CTG TTG GGC ATG AG 
S67900 / NM_080477 
(1638-1769bp) 
 PFKFB2 
(Ser466) 
FWD: TCT TGG ATA AAG GCG CAG AT 
REV: TGT CCA TTT GCA AAC TCC AG 
NM_001033965 
(1403-1774bp) 
 PFKFB3 FWD: CAC GGC GAG AAT GAG TAC AA 
REV: TTC AGC TGA CTG GTC CAC AC 
NM_057135 
(1165-1291bp) 
Human PFKFB1 FWD: CCT GCA AAT CAG GAA GCA GT 
REV: TTT GCA AAC TGC AGG ATC AG 
NM_002625 
(382-503bp) 
 PFKFB2 FWD: TAC GAC TTC TTT CGG CAT GA 
REV: CTC CTC TCC CGG GTT GTA TT 
NM_006212 
(324-453bp) 
 PFKFB2 
(Ser466) 
FWD: CTT AAC GTG GAG GCT GTG AA 
REV: TTG GAC GCC TTA TTG TAT TCG 
NM_006212 
(1361-1470bp) 
 PFKFB3 FWD: CCG TGT GGA ATC CAT CTA CC 
REV: CTG TTG ATG CGA GGC TTT TT 
NM_004566 
(1619-1752bp) 
 
Table 1.  Primer sequences for real-time RT-PCR. 
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LEGENDS TO FIGURES 
 
Figure 1.  Expression of PFKFB isoforms in rat, mouse and human islets and 
MIN6 and INS1E.   RNA was extracted from islets and cell lines and expression of 
PFKFB1, PFKFB2 and PFKFB3 mRNA was determined by real-time RT-PCR.  A-C.  
Primers against rat PFKFB1 (A), PFKFB2 (B), and PFKFB3 (C).  D-F.  Primers 
against mouse PFKFB1 (D), PFKFB2 (E), and PFKFB3 (F).  Results are expressed as 
PFKFB/18S ratio.  n = 3.  G.  Primers against the C-terminus of rat and mouse 
PFKFB2.  Results are representative of 2 experiments.  H.  Primers against human 
PFKFB1, PFKFB2, PFKFB2(C-terminus)  and PFKFB3.  Results represent 4 human 
islet preparations.   
 
 
Figure 2.  Effects of oligomycin and AICAR on fructose 2,6-P2 content.   
A.  MIN6 were incubated with 50µM oligomycin for 2, 5 or 10 min at 5mM glucose.  
Immunoblot for AMPK-Thr172(P) (upper panel) and fructose 2,6-P2 content (F26P2), 
expressed as percentage control. n = 5.  * P < 0.05, relative to no oligomycin.  B-D.  
MIN6 cells were incubated without or with 50, 100 and 200 µM AICAR for 1h at 5 or 
25mM glucose.  B. AMPK-Thr172(P) and fructose 2,6-P2. C. Glycolysis; D.  Insulin 
secretion.  Results are expressed as percentage of 5 mM glucose control.   Control 
values are: fructose 2,6-P2, 6.9 ± 1.26 pmol/mg protein; glycolysis, 128 ± 16 nmol/h 
/mg protein and insulin secretion = 1.5 ± 0.4 µg/mg protein, n=4, * P < 0.05. ** P 
<0.01, relative to 5 mM glucose control.  # P < 0.05, relative to 25mM glucose 
control.  E,F. PFK2 activity determined after 1 h incubation without or with 500 µM 
AICAR. E. MIN6 cells, F.  hepatocytes,   n = 4, * P < 0.05. ** P <0.01 relative to no 
AICAR.  
  
Figure 3.  Effects of glucose on fructose 2,6-P2. 
A.  Mouse and rat islets were incubated with 5 or 25 mM glucose for 1 h.  n = 3 islet 
preparations.  Fructose 2,6-P2 (F26P2) is expressed as fmol/islet.  B.  MIN6 and 
INS1E were incubated with varying glucose concentration (5-35mM) for 1h.  
Fructose 2,6-P2 is expressed as pmol/mg protein.  n = 4.  * P < 0.05, ** P < 0.01, *** 
P < 0.005 relative to 5mM glucose control. 
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Figure 4.  Epiandrosterone suppresses fructose 2,6-P2 in MIN6 and INS1E. 
A-B.  MIN6 (A) and INS1E (B) were incubated for 1 h with varying epiandrosterone 
concentrations at 5 or 25mM glucose.  Fructose 2,6-P2 (F26P2) is expressed as 
pmol/mg protein.  n = 1 (A), or 2 (B).  C.  Insulin secretion was determined in MIN6 
incubated for 1 h without or with 50µM epiandrosterone at 5 or 25mM glucose and is 
expressed as percentage of 5mM glucose.  Control value: 1.5 ± 0.2 µg/mg protein.  n 
= 2.  D.  Fructose 2,6-P2 was determined in MIN6 after 1 h incubation without or with 
25µM epiandrosterone or 500µM AICAR at 25 mM glucose, n=4,  * P < 0.05, *** P 
< 0.005, effect of AICAR; ### P < 0.005, effect of epiandrosterone. 
 
Figure 5.  Silencing of PFK-2/FBPase-2 in INS1E.   
INS1E cells were transfected with either scrambled (-ve) or siRNA against PFKFB2 
and PFKFB3 (FB2 + FB3) and cultured for 72h.   A. PFKFB2 and PFKFB3 mRNA. 
B. PFK-2/FBPase-2 protein determined by immunoblotting and densitometry.  C.  
Fructose 2,6-P2 at 5 and 25mM glucose.  D. Insulin secretion.  E. glycolysis.  F. 
glucokinase activity and protein determined on the 13,000g supernatant after 
sonication.  Results are expressed as percentage of –ve siRNA control.  Control 
values are: fructose 2,6-P2 = 5.8 ± 1.0 pmol/mg protein, insulin secretion = 1.3 ± 0.2 
µg/mg protein, glycolysis = 102 ± 18 nmol/h/mg protein, glucokinase activity = 2.7 ± 
0.2 mU/mg protein.  n = 4.  Immunoblots are representative of 4 experiments.  * P < 
0.05, ** P < 0.01, *** P < 0.005 relative to 5mM control.  # P < 0.05, ## P < 0.01, 
### P < 0.005 relative to –ve siRNA control. 
 
Figure 6.  Alteration of fructose 2,6-P2 in hepatocytes by expression of KA-PFK-
2/FBPase-2 and KD-PFK-2/FBPase-2.   KA-PFK-2/FBPase-2 (KA, A,B) and KD-
PFK-2/FBPase-2 (KD, C,D) were expressed in hepatocytes by incubation for 2h with 
increasing titres of adenoviral vectors (1-3).  After overnight culture, fructose 2,6-P2 
(A,C) and glycolysis (B,D) were determined after a 1h incubation with 25 mM 
glucose with glucagon (100nM) where indicated in C,D.  E. Fructose 2,6-P2 content 
(A,C) versus glycolysis (B,D).  Results are expressed as percentage control.  Control 
values are: fructose 2,6-P2 = 132 ± 21 pmol/mg protein, glycolysis = 98 ± 26 
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nmol/h/mg protein.  n = 4 (A,B) or 5 (C,D).  * P < 0.05, *** P < 0.005 relative to 
control. 
 
Figure 7.  Alteration of fructose 2,6-P2 in MIN6 by expression of KA-PFK-
2/FBPase-2 and KD-PFK-2/FBPase-2.    KA-PFK-2/FBPase-2 (A-C) and KD-PFK-
2/FBPase-2 (D-F) were expressed in MIN6 by incubation with increasing titres (1-3) 
of adenovirus for 6h.  After overnight culture, cells were incubated for 1 h with the 
glucose concentration indicated (A-C, 25 and 5mM; D-F, 5 and 15 mM) for 
determination of fructose 2,6-P2 (A,D), glycolysis (B,E) and insulin secretion (C,F).   
Results are expressed as percentage control.  Control values are:  5mM (A-C) = 
fructose 2,6-P2 = 7.1 ± 0.8 pmol/mg protein, glycolysis = 133 ± 22 nmol/h/mg 
protein, insulin secretion = 1.8 ± 0.4 µg/mg protein, 15mM (D-F) = fructose 2,6-P2 = 
17.6 ± 3.3 pmol/mg protein, glycolysis = 208 ± 43 nmol/h/mg protein, insulin 
secretion = 2.6 ± 0.2 µg/mg protein.  n = 5 (A-C) or 6 (D-F).  * P < 0.05, ** P < 0.01 
*** P < 0.005 vs control at 5mM (A-C) or 15mM (D-F) glucose. 
 
Figure 8.  Effect of expression of PFK-2/FBPase-2 on glucokinase activity.  
A,B.  KA-PFK-2/FBPase-2 was expressed in MIN6 as in Fig. 7.  After overnight 
culture, cells were extracted either by sonication and centrifugation at 13,000g (A) or 
by permeabilisation with 0.04mg/ml digitonin for 4min (B) and glucokinase activity 
determined.  n = 5 (A) or 4 (B).  C,D.  KA-PFK-2/FBPase-2 and rat liver glucokinase 
were expressed in MIN6 cells by incubation with adenoviral vectors for 6h.  After 
overnight culture glucokinase activity was determined on the sonicated supernatant 
(C) and insulin secretion determined at 5 or 25mM glucose in the absence or presence 
of 10µM GKA [27].  Results are expressed as percentage control.  Control values are: 
A. glucokinase activity = 1.49 ± 0.3 mU/mg protein, C. glucokinase activity = 1.02 
mU/mg protein, D. insulin secretion = 0.51 ± 0.06 µg/mg protein.  n = 1 based on 3 
replicates within an individual experiment.  ** P <0.01 relative to control. 
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